- Associated Press•2 months ago
DOYLESTOWN, Pa. (AP) — The Pennsylvania-based maker of Cold-Eeze throat lozenges has announced that it has sold the brand to another pharmaceutical company for $50 million.
- American City Business Journals•2 months ago
ProPhase Labs Inc. has entered into an agreement to sell its Cold-Eeze cold remedy brand to a wholly owned subsidiary of Mylan N.V. for $50 million. The Philadelphia Business Journals first reported the Doylestown company was exploring the potential sale of the product line in August. The Cold-Eeze brand began as zinc lozenges used to shorten the duration of cold, but the formulations were later expanded to include "Gummies," quick-melts and oral spray versions of the product.
- TheStreet.com•2 months ago
Cold-Eeze will become Mylan's largest U.S. over-the-counter brand franchise, and builds upon its $1 billion global OTC business.
PRPH : Summary for ProPhase Labs, Inc. - Yahoo Finance
ProPhase Labs, Inc. (PRPH)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Bid||1.96 x 100|
|Day's Range||2.04 - 2.13|
|52 Week Range||1.08 - 2.45|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-10.14|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|